Neuren Announces Results of the NNZ-2566 Clinical Trial for Rett Syndrome

Cincinnati, Ohio (PRWEB) November 11, 2014 Neuren Pharmaceuticals’ human clinical trial using NNZ-2566 as a potential treatment for Rett syndrome (a trial supported by Rettsyndrome.org) was completed in September of this year. On November 11, Neuren announced the results of this phase 2 placebo-controlled study, which investigated the dosing of NNZ-2566 for safety and tolerability ...